Abstract | BACKGROUND: METHODS:
Formalin-fixed, paraffin-embedded pretherapeutic biopsies of patients treated by radiochemotherapy followed by esophagectomy were analyzed. The response was determined by histopathological tumor regression grading. miRNA profiling was performed by microarray analysis (Agilent platform) in 16 non-responders and 15 responders. Differentially expressed miRNAs were confirmed by real-time quantitative PCR (qRT-PCR) in an expanded cohort of 53 cases. RESULTS: The miRNA profiles within and between non-responders and responders were highly similar (r = 0.96, 0.94 and 0.95). However, 12 miRNAs were differentially expressed (> twofold; p ≤ 0.025): non-responders showed upregulation of hsa-miR-1323, hsa-miR-3678-3p, hsv2-miR-H7-3p, hsa-miR-194*, hsa-miR-3152, kshv-miR-K12-4-3p, hsa-miR-665 and hsa-miR-3659 and downregulation of hsa-miR-126*, hsa-miR-484, hsa-miR-330-3p and hsa-miR-3653. qRT-PCR analysis confirmed the microarray findings for hsa-miR-194* and hsa-miR-665 (p < 0.001 each) with AUC values of 0.811 (95% CI 0.694-0.927) and 0.817 (95% CI 0.704-0.930), respectively, in ROC analysis. CONCLUSIONS: Our results indicate that miRNAs are involved in the therapeutic response in ESCC and suggest that miRNA profiles could facilitate pretherapeutic patient selection.
|
Authors | Julia Slotta-Huspenina, Enken Drecoll, Marcus Feith, Daniel Habermehl, Stephanie Combs, Wilko Weichert, Marcus Bettstetter, Karen Becker, Rupert Langer |
Journal | Journal of translational medicine
(J Transl Med)
Vol. 16
Issue 1
Pg. 109
(04 25 2018)
ISSN: 1479-5876 [Electronic] England |
PMID | 29695253
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Chemoradiotherapy
- Drug Resistance, Neoplasm
(genetics)
- Esophageal Squamous Cell Carcinoma
(genetics, surgery, therapy)
- Female
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- MicroRNAs
(genetics, metabolism)
- Middle Aged
- Multivariate Analysis
- Neoadjuvant Therapy
- Proportional Hazards Models
- ROC Curve
- Survival Analysis
|